Breast Cancer Therapeutics in Major Developed Markets Trends to 2021 2 | Page 7

8 Deals and Strategic Consolidations 84
8.1 Licensing Deals 84
8.1.1 Sprint Bioscience Enters Licensing Agreement with Bayer HealthCare 88
8.1.2 Takeda Enters Licensing Agreement with ImmunoGen 88
8.1.3 Oncothyreon Enters Licensing Agreement with Array BioPharma for ONT-380 89
8.1.4 Halozyme Therapeutics Enters Licensing Agreement with Janssen Biotech 89
8.1.5 CTI BioPharma Enters Licensing Agreement with Servier for Pixuvri 89
8.2 Co-development Deals 90
8.2.1 MacroGenics Enters Agreement with Merck 93
8.2.2 Color Genomics Partners with University of California Health 93
8.2.3 Lycera Enters Co-development Agreement with Celgene 93
8.2.4 Roche Holding Enters Agreement with Oryzon to Develop Epigenetics-Based Medicines 94
8.2.5 Tracon Enters Co-development Agreement with Santen Pharma 94
9 Appendix 95
9.1 All Pipeline Drugs by Phase of Development 95
9.1.1 Discovery 95
9.1.2 Preclinical 99
9.1.3 IND/CTA-filed 116
9.1.4 Phase I 117
9.1.5 Phase II 135
9.1.6 Phase III 148
9.1.7 Pre-registration 152
9.2 Market Forecasts to 2021 152
9.2.1 Global 152
9.2.2 US 153